tiprankstipranks
Trending News
More News >

Thiogenesis to Showcase Promising Mitochondrial Treatments at UMDF Conference

Story Highlights
Thiogenesis to Showcase Promising Mitochondrial Treatments at UMDF Conference

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Thiogenesis Therapeutics Corp ( (TSE:TTI) ) is now available.

Thiogenesis Therapeutics Corp announced that its CEO, Dr. Patrice Rioux, will present at the UMDF’s Mitochondrial Medicine 2025 Conference, highlighting the company’s leading clinical programs in MELAS and Leigh Syndrome Spectrum. The presentation will focus on their novel thiol drug, TTI-0102, which is in Phase 2 clinical trials in Europe and the U.S. The drug is designed to enhance intracellular levels of glutathione and taurine to combat oxidative stress, a core issue in mitochondrial disorders. This announcement underscores Thiogenesis’ commitment to advancing treatments for mitochondrial diseases and may strengthen its position in the biopharmaceutical industry.

More about Thiogenesis Therapeutics Corp

Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company focused on developing sulfur-based therapeutics for rare pediatric and inherited mitochondrial disorders.

Average Trading Volume: 32,360

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$36.12M

See more data about TTI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1